CRSP – CRISPR Therapeutics AG
Float Short %
27.23
Margin Of Safety %
Put/Call OI Ratio
0.52
EPS Next Q Diff
0.22
EPS Last/This Y
-1.72
EPS This/Next Y
1.42
Price
54.31
Target Price
78.68
Analyst Recom
1.94
Performance Q
44.74
Relative Volume
0.52
Beta
1.81
Ticker: CRSP
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | CRSP | 64.76 | 0.61 | 0.44 | 139231 |
| 2025-07-28 | CRSP | 63.75 | 0.63 | 0.51 | 129511 |
| 2025-07-29 | CRSP | 59.04 | 0.62 | 0.53 | 130595 |
| 2025-07-30 | CRSP | 57.68 | 0.62 | 0.22 | 134617 |
| 2025-07-31 | CRSP | 56.23 | 0.61 | 0.22 | 138532 |
| 2025-08-01 | CRSP | 56.11 | 0.59 | 0.68 | 142010 |
| 2025-08-04 | CRSP | 59.6 | 0.57 | 0.44 | 137607 |
| 2025-08-05 | CRSP | 55.58 | 0.56 | 0.45 | 143816 |
| 2025-08-06 | CRSP | 56.33 | 0.56 | 0.38 | 145857 |
| 2025-08-07 | CRSP | 55.97 | 0.56 | 0.23 | 149364 |
| 2025-08-08 | CRSP | 55.02 | 0.55 | 0.26 | 150465 |
| 2025-08-11 | CRSP | 55.48 | 0.55 | 0.53 | 141718 |
| 2025-08-12 | CRSP | 56.6 | 0.56 | 0.23 | 143853 |
| 2025-08-13 | CRSP | 58.96 | 0.55 | 0.13 | 145294 |
| 2025-08-14 | CRSP | 58.83 | 0.54 | 0.26 | 148413 |
| 2025-08-15 | CRSP | 59.68 | 0.53 | 0.43 | 154522 |
| 2025-08-18 | CRSP | 57.61 | 0.49 | 0.47 | 126191 |
| 2025-08-19 | CRSP | 54.04 | 0.50 | 0.38 | 128976 |
| 2025-08-20 | CRSP | 53.05 | 0.51 | 0.71 | 131806 |
| 2025-08-21 | CRSP | 52.83 | 0.52 | 0.80 | 134393 |
| 2025-08-22 | CRSP | 54.32 | 0.52 | 0.31 | 136014 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | CRSP | 64.76 | 6.1 | 144.0 | -5.39 |
| 2025-07-28 | CRSP | 63.83 | 6.1 | 141.5 | -5.39 |
| 2025-07-29 | CRSP | 59.02 | 6.1 | 170.5 | -5.39 |
| 2025-07-30 | CRSP | 57.68 | 6.1 | 145.9 | -5.39 |
| 2025-07-31 | CRSP | 56.26 | 6.1 | 147.1 | -5.39 |
| 2025-08-01 | CRSP | 56.09 | 6.1 | 136.2 | -5.39 |
| 2025-08-04 | CRSP | 59.59 | 6.1 | 102.6 | -5.39 |
| 2025-08-05 | CRSP | 55.59 | 6.1 | 169.0 | -5.39 |
| 2025-08-06 | CRSP | 56.35 | -25.9 | 206.1 | -6.53 |
| 2025-08-07 | CRSP | 55.96 | -25.9 | 215.9 | -6.53 |
| 2025-08-08 | CRSP | 55.00 | -27.1 | 221.0 | -5.87 |
| 2025-08-11 | CRSP | 55.45 | -27.1 | 197.9 | -5.87 |
| 2025-08-12 | CRSP | 56.65 | -28.6 | 190.8 | -6.01 |
| 2025-08-13 | CRSP | 57.33 | -28.6 | 195.6 | -6.01 |
| 2025-08-14 | CRSP | 58.85 | -28.6 | 188.9 | -6.01 |
| 2025-08-15 | CRSP | 59.69 | -28.6 | 194.8 | -6.01 |
| 2025-08-18 | CRSP | 57.58 | -28.6 | 219.4 | -6.01 |
| 2025-08-19 | CRSP | 54.16 | -27.7 | 231.3 | -6.06 |
| 2025-08-20 | CRSP | 53.03 | -27.7 | 212.6 | -6.06 |
| 2025-08-21 | CRSP | 52.83 | -27.7 | 204.3 | -6.06 |
| 2025-08-22 | CRSP | 54.31 | -27.7 | 187.5 | -6.06 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | CRSP | 24.59 | 0.04 | 30.93 |
| 2025-07-28 | CRSP | 24.59 | 7.75 | 30.93 |
| 2025-07-29 | CRSP | 24.59 | 7.75 | 30.93 |
| 2025-07-30 | CRSP | 24.59 | 7.75 | 30.93 |
| 2025-07-31 | CRSP | 24.59 | 7.75 | 30.93 |
| 2025-08-01 | CRSP | 24.59 | 7.75 | 30.93 |
| 2025-08-04 | CRSP | 24.59 | 7.33 | 30.93 |
| 2025-08-05 | CRSP | 24.59 | 7.33 | 30.93 |
| 2025-08-06 | CRSP | 24.59 | 7.33 | 30.93 |
| 2025-08-07 | CRSP | 23.06 | 7.33 | 29.37 |
| 2025-08-08 | CRSP | 23.70 | 7.33 | 29.37 |
| 2025-08-11 | CRSP | 23.70 | 5.03 | 29.37 |
| 2025-08-12 | CRSP | 23.70 | 5.03 | 27.22 |
| 2025-08-13 | CRSP | 23.70 | 5.03 | 27.22 |
| 2025-08-14 | CRSP | 23.59 | 5.03 | 27.23 |
| 2025-08-15 | CRSP | 23.59 | 5.03 | 27.23 |
| 2025-08-18 | CRSP | 23.59 | 9.46 | 27.23 |
| 2025-08-19 | CRSP | 23.17 | 9.46 | 27.23 |
| 2025-08-20 | CRSP | 24.14 | 9.46 | 27.23 |
| 2025-08-21 | CRSP | 24.14 | 9.46 | 27.23 |
| 2025-08-22 | CRSP | 24.72 | 9.46 | 27.23 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.29
Avg. EPS Est. Current Quarter
-1.29
Avg. EPS Est. Next Quarter
-1.07
Insider Transactions
24.72
Institutional Transactions
9.46
Beta
1.81
Average Sales Estimate Current Quarter
8
Average Sales Estimate Next Quarter
17
Fair Value
Quality Score
19
Growth Score
37
Sentiment Score
36
Actual DrawDown %
75.3
Max Drawdown 5-Year %
-85.1
Target Price
78.68
P/E
Forward P/E
PEG
P/S
129.84
P/B
2.81
P/Free Cash Flow
EPS
-5.42
Average EPS Est. Cur. Y
-6.06
EPS Next Y. (Est.)
-4.64
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1229.43
Relative Volume
0.52
Return on Equity vs Sector %
-52
Return on Equity vs Industry %
-39.1
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.72
EBIT Estimation
187.5
CRISPR Therapeutics AGSector: Healthcare
Industry: Biotechnology
Employees: 393
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
stock quote shares CRSP – CRISPR Therapeutics AG Stock Price stock today
news today CRSP – CRISPR Therapeutics AG stock forecast ,stock prediction 2023 2024 2025
marketwatch CRSP – CRISPR Therapeutics AG yahoo finance google finance
stock history CRSP – CRISPR Therapeutics AG invest stock market
stock prices CRSP premarket after hours
ticker CRSP fair value insiders trading